Trial Profile
Second-line gefitinib vs erlotinib in patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2012
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Jan 2012 Results published in Lung Cancer.
- 05 Nov 2010 New trial record.